logo
logo
FUNDING SIGNALS

Real Signals. Real Leads. Real Deals.

The only platform that turns real-time signals into your perfect leads

Know Who, Why, and When to reach out — instantly.

FundzWatch™ AI Scoring
10-25 leads daily
Real-time alerts
★★★★★
4.8/5 on G2• High Performer Fall 2025
Used by teams at LinkedIn, HubSpot & Oracle
🔒 app.fundz.net

TechCorp

📍 San Francisco👥 85
92
Post-Funding
⭐ Ideal Match

Just raised $40M Series B - high purchase intent window

Mpc Therapeutics Announces Completion Of Its Chf 1.5M Seed-Funding Round To Improve Car-T Cancer Therapies.

Jan 11, 2023•over 2 years ago

Round Type

seed

GenevaTherapeuticsBiotechnologyHealth Care

Investors

Plutus Investment Group

Description

MPC Therapeutics (MPC Tx), a Swiss biotechnology company focused on metabolism and rejuvenation, today announced the closing of its CHF 1.5 million seed-funding round. Funds will serve to advance MPC Tx’s proprietary small molecule towards clinical trials and open new therapeutic applications. The funding round was led by Plutus Investment Group, a London-based family office, and received additional funding from business angels.

Company Information

Company

MPC Therapeutics

Location

Geneva, Alabama, United States

About

At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info.

Company News

(10 articles)
Fri, 20 Jun 2025 07:00:00 GMT

Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide - PR Newswire

Wed, 05 Feb 2025 08:00:00 GMT

Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier - ScienceDirect.com

Sat, 18 Jan 2025 08:00:00 GMT

IPS HEART’s Secures Orphan Drug Designation for iPSC-Derived Mesenchymal Progenitor Cell (MPC) Therapy, GIVI-MPC - BioInformant

Mon, 13 Jan 2025 08:00:00 GMT

FDA Grants Orphan Drug Designation to IPS HEART’s GIVI-MPC Stem Cell Therapy for Becker Muscular Dystrophy - Business Wire

Thu, 23 Feb 2023 08:00:00 GMT

GIVI-MPC wins FDA orphan drug status as Duchenne treatment –... - Muscular Dystrophy News

Mon, 27 Feb 2023 08:00:00 GMT

Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure - JACC Journals

Wed, 01 Mar 2023 08:00:00 GMT

Mitochondrial pyruvate metabolism regulates the activation of quiescent adult neural stem cells - Science | AAAS

Tue, 13 Nov 2018 08:00:00 GMT

Mesoblast defends stem cell therapy for heart failure after trial miss - Fierce Biotech

Mon, 24 Jun 2019 07:00:00 GMT

Mesoblast's Mesenchymal Precursor Cell (MPC) Therapy Receives Orphan Drug Designation - BioInformant

Mon, 24 Jul 2023 07:00:00 GMT

IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapy’s Ability to Create New Skeletal Muscle in Aged Mice - Business Wire

FundzWatch™ Score

76
Medium Activity

Related People

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers